
An international study has found an increased risk of Guillain-Barré syndrome (GBS) following SARS-CoV-2 infection and after vaccination with adenoviral …

Hansa Biopharma will present data from its 15-HMedIdeS-09 phase 2 study of imlifidase for treating Guillain-Barré syndrome (GBS) at the …
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion

